Isradipine

Dihydropyridine Calcium Channel Blocker — CARDIOVASCULAR SYSTEM

Key facts

Isradipine is an ofp drug in the Dihydropyridine Calcium Channel Blocker class catalogued in DrugCentral. It was first approved by the FDA in 1990. Its mechanism of action is classified as Calcium Channel Antagonists. DrugCentral lists 9 molecular targets, including CACNA1D, CACNA1C and Cacna1c. Recorded indications include Hypertensive disorder.

• Approval status: ofp (first approved 1990 by the FDA).
• Drug class: Dihydropyridine Calcium Channel Blocker.
• Mechanism of action: Calcium Channel Antagonists.
• Molecular targets: CACNA1D, CACNA1C, Cacna1c and CACNA1C (9 listed in DrugCentral).
• Indications: Hypertensive disorder.
• ATC code: C08CA03 (Dihydropyridine derivatives).
• Molecular formula: C19H21N3O5; molecular weight 371.39 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Hypertensive disorder

Off-label uses (2)

• Angina pectoris
• Raynaud's phenomenon

Contraindications (6)

• Chronic heart failure
• Coronary arteriosclerosis
• Disease of liver
• Low blood pressure
• Myocardial infarction
• Peripheral edema

Mechanism & targets

• Mechanism of action (MoA): Calcium Channel Antagonists
• Established pharmacologic class: Dihydropyridine Calcium Channel Blocker

Molecular targets (9)

Target	Gene	Action	Activity
Voltage-dependent L-type calcium channel subunit alpha-1D	CACNA1D	other	IC50 9.30
Voltage-dependent L-type calcium channel subunit alpha-1C	CACNA1C	other	IC50 8.80
Voltage-dependent L-type calcium channel subunit alpha-1C	Cacna1c	other	IC50 7.50
Voltage-dependent L-type calcium channel subunit alpha-1C	CACNA1C	unknown	IC50 6.97
Voltage-dependent L-type calcium channel subunit alpha-1F	Cacna1f	other	IC50 6.70
Voltage-dependent L-type calcium channel subunit alpha-1D	Cacna1d	unknown	IC50 6.66
Voltage-dependent T-type calcium channel subunit alpha-1H	CACNA1H	unknown	Ki 5.51
Potassium voltage-gated channel subfamily H member 2	KCNH2	unknown	IC50 4.30
Nuclear receptor subfamily 1 group I member 2	NR1I2	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1990-12-20	FDA	—	SMITHKLINE BEECHAM

ATC classification

ATC code	Therapeutic hierarchy
C08CA03	CARDIOVASCULAR SYSTEM › CALCIUM CHANNEL BLOCKERS › SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS › Dihydropyridine derivatives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Diverticulitis intestinal perforated	48.4
Retinal disorder	43.2
Tubulointerstitial nephritis	40.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Isradipine is on its molecule page.

• Molecular formula: C₁₉H₂₁N₃O₅
• Molecular weight: 371.39 g/mol
• CAS number: 75695-93-1
• InChIKey: HMJIYCCIJYRONP-UHFFFAOYSA-N
• PubChem CID: 3784

COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Isradipine used for?

DrugCentral lists the following indications for Isradipine: Hypertensive disorder.

How does Isradipine work?

Isradipine is classified as Calcium Channel Antagonists; its molecular targets in DrugCentral include CACNA1D, CACNA1C, Cacna1c and CACNA1C.

When was Isradipine first approved?

Isradipine was first approved by the FDA in 1990.

What drug class does Isradipine belong to?

Isradipine is in the Dihydropyridine Calcium Channel Blocker class.

What is the chemical formula of Isradipine?

Isradipine has the molecular formula C19H21N3O5 and a molecular weight of 371.39 g/mol.

Sources

• DrugCentral drug card 1511 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1648 — compound record and bioactivity
• PubChem CID 3784 — chemical identifiers
• DrugBank DB00270 — drug record
• FDA UNII YO1UK1S598 — substance identity
• DailyMed: FDA labels for Isradipine — current prescribing information (label search)
• UniProt Q01668 (CACNA1D) — target protein
• UniProt Q13936 (CACNA1C) — target protein
• UniProt O95180 (CACNA1H) — target protein
• UniProt Q12809 (KCNH2) — target protein
• UniProt O75469 (NR1I2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.